Keyword Analysis & Research: axsome therapeutics


Keyword Analysis

Keyword CPC PCC Volume Score Length of keyword
axsome therapeutics1.46133096319
axsome1.680.51259486
therapeutics0.030.88222312

Keyword Research: People who searched axsome therapeutics also searched

Keyword CPC PCC Volume Score
axsome therapeutics0.680.3936142
axsome therapeutics stock0.830.986934
axsome therapeutics careers0.070.1899710
axsome therapeutics news0.790.8951736
axsome therapeutics website1.560.269959
axsome therapeutics stock price0.540.452817
axsome therapeutics aktie0.251147558
axsome therapeutics ticker1.580.617633
axsome therapeutics news today0.180.9464854
axsome therapeutics investor relations0.350.8553221
axsome therapeutics stock forecast0.360.8810457
axsome therapeutics pipeline1.720.1177493
axsome therapeutics yahoo finance0.210.327118
axsome therapeutics stock price today live1.350.8549874
axsome therapeutics stock price today news0.760.6862120
axsome therapeutics inc0.40.4542396
clinical trials advance-2 axsome therapeutics10.8383133
advance 1 axsome therapeutics1.580.4370949

Search Results related to axsome therapeutics on Search Engine

  • Expanding Treatment for CNS Conditions - Axsome Therapeutics

    axsome.com

    https://www.axsome.com/

    WEBAxsome is developing innovative treatments including AXS-05, AXS-07, AXS-12, and AXS‑14. Axsome focuses on CNS conditions including depression, Alzheimer's disease agitation, migraine, narcolepsy and fibromyalgia.

    DA: 72 PA: 2 MOZ Rank: 27

  • About Axsome - Axsome Therapeutics

    axsome.com

    https://www.axsome.com/about-axsome

    WEBAxsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for central nervous system (CNS) conditions that have limited treatment options. Through development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions.

    DA: 25 PA: 68 MOZ Rank: 97

  • Axsome Therapeutics, Inc. (AXSM) - Yahoo Finance

    yahoo.com

    https://finance.yahoo.com/quote/AXSM

    WEBAxsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States.

    DA: 14 PA: 83 MOZ Rank: 77

  • Axsome Therapeutics Highlights Innovative Neuroscience …

    yahoo.com

    https://finance.yahoo.com/news/axsome-therapeutics-highlights-innovative-neuroscience-110000063.html

    WEB4 days ago · Axsome Therapeutics, Inc. is a biopharmaceutical company developing and delivering novel therapies for central nervous system (CNS) conditions that have limited treatment options.

    DA: 28 PA: 8 MOZ Rank: 63

  • Axsome Therapeutics Highlights Innovative ... - Markets Insider

    businessinsider.com

    https://markets.businessinsider.com/news/stocks/axsome-therapeutics-highlights-innovative-neuroscience-portfolio-at-the-american-academy-of-neurology-aan-2024-annual-meeting-1033248685

    WEB4 days ago · Axsome Therapeutics, Inc. is a biopharmaceutical company developing and delivering novel therapies for central nervous system (CNS) conditions that have limited treatment options.

    DA: 93 PA: 42 MOZ Rank: 10


  • Axsome Therapeutics Announces FDA Approval of AUVELITY™, …

    yahoo.com

    https://finance.yahoo.com/news/axsome-therapeutics-announces-fda-approval-104500101.html

    WEBNEW YORK, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...

    DA: 41 PA: 77 MOZ Rank: 18

  • Axsome Therapeutics Announces FDA Acceptance of New Drug

    globenewswire.com

    https://www.globenewswire.com/news-release/2021/09/14/2296511/33090/en/Axsome-Therapeutics-Announces-FDA-Acceptance-of-New-Drug-Application-for-AXS-07-for-the-Acute-Treatment-of-Migraine.html

    WEBNEW YORK, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...

    DA: 14 PA: 34 MOZ Rank: 65

  • Axsome Therapeutics Announces AXS-05 Achieves Primary and

    globenewswire.com

    https://www.globenewswire.com/news-release/2021/08/09/2276951/33090/en/Axsome-Therapeutics-Announces-AXS-05-Achieves-Primary-and-Key-Secondary-Endpoints-in-the-MERIT-Phase-2-Trial-in-Treatment-Resistant-Depression.html

    WEBNEW YORK, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...

    DA: 93 PA: 1 MOZ Rank: 18

  • Axsome Therapeutics Highlights Innovative Neuroscience

    biospace.com

    https://www.biospace.com/article/releases/axsome-therapeutics-highlights-innovative-neuroscience-portfolio-at-the-american-academy-of-neurology-aan-2024-annual-meeting/

    WEB4 days ago · Axsome Therapeutics, Inc., a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders, announced presentations highlighting its innovative psychiatry and neurology pipeline at the American Academy of Neurology 2024 annual meeting, being held April 13-18, 2024, in …

    DA: 33 PA: 80 MOZ Rank: 9

  • Axsome Therapeutics Announces FDA Approval of AUVELITY™, …

    globenewswire.com

    https://www.globenewswire.com/news-release/2022/08/19/2501453/33090/en/Axsome-Therapeutics-Announces-FDA-Approval-of-AUVELITY-the-First-and-Only-Oral-NMDA-Receptor-Antagonist-for-the-Treatment-of-Major-Depressive-Disorder-in-Adults.html

    WEBNEW YORK, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...

    DA: 45 PA: 59 MOZ Rank: 89